Gary Lynch

When Dr. Gary Lynch talks, Wall Street listens. The engaging, world-renowned UC Irvine neuroscientist told reporters at a recent Washington science convention that European studies suggest his experimental drug Ampalex enhances memory in healthy people. He noted government plans to test it in Alzheimer's patients next year. Over the next two days, shares of Cortex Pharmaceuticals Inc., whose future rides on the Alzheimer's trials, more than doubled in price to $6.32.

Reflecting in the spring of 2005 on his lab's recent successes, which he regarded as a culmination of decades of work, UC Irvine neuroscientist Gary Lynch said: "This will be a moment when all the tribes of neuroscience come to the same campfire." He was wrong. There was no reaction. Nothing. Initially, he couldn't even get a short paper on a crucial visualization experiment published.

Lynch Lab sits between a toll road and the UC Irvine main campus, in an office park of indistinguishable low-rise, beige-on-beige stucco buildings. Neuroscientist Gary Lynch had moved his lab and office -- for a while, just a desk in a hallway -- numerous times during his Irvine career, often as the result of some feud or slight.

Lynch Lab sits between a toll road and the UC Irvine main campus, in an office park of indistinguishable low-rise, beige-on-beige stucco buildings. Neuroscientist Gary Lynch had moved his lab and office -- for a while, just a desk in a hallway -- numerous times during his Irvine career, often as the result of some feud or slight.

The myth of modern science, that it proceeds carefully, rationally, incrementally, building bit by bit from rock-solid foundations to impregnable fortresses of fact, comes unraveled in contemporary neuroscience. Fortresses, entire kingdoms of neuroscience have been built on what turn out to be frail premises that get swept away entirely when the next new thing comes along.

Reflecting in the spring of 2005 on his lab's recent successes, which he regarded as a culmination of decades of work, UC Irvine neuroscientist Gary Lynch said: "This will be a moment when all the tribes of neuroscience come to the same campfire." He was wrong. There was no reaction. Nothing. Initially, he couldn't even get a short paper on a crucial visualization experiment published.

Richard Granger remembers that when he and Gary Lynch, both UC Irvine professors, planned their experiment back in the '80s, they agreed not to tell anyone about it. "This was a ridiculous thing we were doing," Granger says. "After our first paper was published, people looked at our progress like people look at a street accident--with morbid curiosity."

Credit Suisse First Boston on Monday said it named Gary Lynch vice chairman in charge of stock research and legal and compliance issues, as the brokerage attempts to bolster its analysts' image in the aftermath of allegations of conflicts of interest across the industry. Lynch, who was enforcement director of the Securities and Exchange Commission from 1985 to 1989, was one of CSFB Chief Executive John Mack's first hires and had already been the firm's global general counsel.

The first time I spoke with the neuroscientist Gary Lynch, the conversation went something like this: Me: I'm interested in spending time in a laboratory like yours, where the principal focus is the study of memory. I'd like to explain how memory functions and fails, and why, and use the work in the lab as a means to illustrate how we know what we know. Lynch: You'd be welcome to come here. This would actually be a propitious time to be in the lab. Me: Why's that? Lynch: Because we're about to nail this mother to the door.

Mattel to Review Accounting Allegations: The El Segundo-based toy manufacturer said it has asked the audit committee of its board of directors to conduct an independent review of claims that it boosted its earnings through improper accounting practices. The company said the committee selected Gary Lynch, former enforcement director of the Securities and Exchange Commission, to lead the probe.

The myth of modern science, that it proceeds carefully, rationally, incrementally, building bit by bit from rock-solid foundations to impregnable fortresses of fact, comes unraveled in contemporary neuroscience. Fortresses, entire kingdoms of neuroscience have been built on what turn out to be frail premises that get swept away entirely when the next new thing comes along.

The first time I spoke with the neuroscientist Gary Lynch, the conversation went something like this: Me: I'm interested in spending time in a laboratory like yours, where the principal focus is the study of memory. I'd like to explain how memory functions and fails, and why, and use the work in the lab as a means to illustrate how we know what we know. Lynch: You'd be welcome to come here. This would actually be a propitious time to be in the lab. Me: Why's that? Lynch: Because we're about to nail this mother to the door.

Credit Suisse First Boston on Monday said it named Gary Lynch vice chairman in charge of stock research and legal and compliance issues, as the brokerage attempts to bolster its analysts' image in the aftermath of allegations of conflicts of interest across the industry. Lynch, who was enforcement director of the Securities and Exchange Commission from 1985 to 1989, was one of CSFB Chief Executive John Mack's first hires and had already been the firm's global general counsel.

When Dr. Gary Lynch talks, Wall Street listens. The engaging, world-renowned UC Irvine neuroscientist told reporters at a recent Washington science convention that European studies suggest his experimental drug Ampalex enhances memory in healthy people. He noted government plans to test it in Alzheimer's patients next year. Over the next two days, shares of Cortex Pharmaceuticals Inc., whose future rides on the Alzheimer's trials, more than doubled in price to $6.32.

Richard Granger remembers that when he and Gary Lynch, both UC Irvine professors, planned their experiment back in the '80s, they agreed not to tell anyone about it. "This was a ridiculous thing we were doing," Granger says. "After our first paper was published, people looked at our progress like people look at a street accident--with morbid curiosity."

Gary Lynch, director of enforcement for the Securities and Exchange Commission, spoke at the American Bar Assn.'s annual meeting and said he expects the pending insider trading cases to be filed by Sept. 30. Some of them involve information obtained from the Swiss government, he added, saying the information was gathered under the 1982 agreement that allows the United States to penetrate Swiss privacy laws under certain conditions.

The Securities and Exchange Commission said today that enforcement director Gary Lynch, who led the agency's crackdown on insider trading on Wall Street, would leave the commission staff in mid-July. Lynch, as the agency's top enforcement officer since 1985, was the prime mover behind the commission's biggest cases in recent years, including the settlements with stock speculator Ivan Boesky and Drexel Burnham Lambert Inc. Lynch had joined the commission in 1976 as a staff attorney.